190 related articles for article (PubMed ID: 17360982)
1. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.
Nakamachi T; Nomiyama T; Gizard F; Heywood EB; Jones KL; Zhao Y; Fuentes L; Takebayashi K; Aso Y; Staels B; Inukai T; Bruemmer D
Diabetes; 2007 Jun; 56(6):1662-70. PubMed ID: 17360982
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-12 gene regulation by a PPAR alpha agonist in human monocyte-derived macrophages.
Souissi IJ; Billiet L; Cuaz-Pérolin C; Slimane MN; Rouis M
Exp Cell Res; 2008 Nov; 314(18):3405-14. PubMed ID: 18823978
[TBL] [Abstract][Full Text] [Related]
3. Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways.
Ogawa D; Stone JF; Takata Y; Blaschke F; Chu VH; Towler DA; Law RE; Hsueh WA; Bruemmer D
Circ Res; 2005 Apr; 96(7):e59-67. PubMed ID: 15790955
[TBL] [Abstract][Full Text] [Related]
4. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.
Grau R; Punzón C; Fresno M; Iñiguez MA
Biochem J; 2006 Apr; 395(1):81-8. PubMed ID: 16343055
[TBL] [Abstract][Full Text] [Related]
6. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
[TBL] [Abstract][Full Text] [Related]
7. Thioredoxin-1 and its natural inhibitor, vitamin D3 up-regulated protein 1, are differentially regulated by PPARalpha in human macrophages.
Billiet L; Furman C; Cuaz-Pérolin C; Paumelle R; Raymondjean M; Simmet T; Rouis M
J Mol Biol; 2008 Dec; 384(3):564-76. PubMed ID: 18848838
[TBL] [Abstract][Full Text] [Related]
8. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.
Hiuge A; Tenenbaum A; Maeda N; Benderly M; Kumada M; Fisman EZ; Tanne D; Matas Z; Hibuse T; Fujita K; Nishizawa H; Adler Y; Motro M; Kihara S; Shimomura I; Behar S; Funahashi T
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):635-41. PubMed ID: 17194889
[TBL] [Abstract][Full Text] [Related]
9. Effect of peroxisome proliferator-activated receptor alpha on human angiotensinogen promoter.
Shimamoto Y; Hirota K; Fukamizu A
Int J Mol Med; 2004 May; 13(5):729-33. PubMed ID: 15067378
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate induces plasminogen activator inhibitor-1 gene expression in a CLOCK-dependent circadian manner.
Oishi K; Koyanagi S; Matsunaga N; Kadota K; Ikeda E; Hayashida S; Kuramoto Y; Shimeno H; Soeda S; Ohdo S
Mol Pharmacol; 2010 Jul; 78(1):135-41. PubMed ID: 20400680
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists down-regulate alpha2-macroglobulin expression by a PPARalpha-dependent mechanism.
González MC; Corton JC; Cattley RC; Herrera E; Bocos C
Biochimie; 2009 Aug; 91(8):1029-35. PubMed ID: 19497347
[TBL] [Abstract][Full Text] [Related]
12. Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver.
Oishi K; Uchida D; Ishida N
FEBS Lett; 2008 Oct; 582(25-26):3639-42. PubMed ID: 18840432
[TBL] [Abstract][Full Text] [Related]
13. The Interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver.
Stienstra R; Mandard S; Tan NS; Wahli W; Trautwein C; Richardson TA; Lichtenauer-Kaligis E; Kersten S; Müller M
J Hepatol; 2007 May; 46(5):869-77. PubMed ID: 17321000
[TBL] [Abstract][Full Text] [Related]
14. Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle.
De Souza AT; Cornwell PD; Dai X; Caguyong MJ; Ulrich RG
Toxicol Sci; 2006 Aug; 92(2):578-86. PubMed ID: 16707586
[TBL] [Abstract][Full Text] [Related]
15. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence.
Zambon A; Gervois P; Pauletto P; Fruchart JC; Staels B
Arterioscler Thromb Vasc Biol; 2006 May; 26(5):977-86. PubMed ID: 16424352
[TBL] [Abstract][Full Text] [Related]
16. CREB mediates UTP-directed arterial smooth muscle cell migration and expression of the chemotactic protein osteopontin via its interaction with activator protein-1 sites.
Jalvy S; Renault MA; Lam Shang Leen L; Belloc I; Reynaud A; Gadeau AP; Desgranges C
Circ Res; 2007 May; 100(9):1292-9. PubMed ID: 17413042
[TBL] [Abstract][Full Text] [Related]
17. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
Guo L; Fang H; Collins J; Fan XH; Dial S; Wong A; Mehta K; Blann E; Shi L; Tong W; Dragan YP
BMC Bioinformatics; 2006 Sep; 7 Suppl 2(Suppl 2):S18. PubMed ID: 17118139
[TBL] [Abstract][Full Text] [Related]
18. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
[TBL] [Abstract][Full Text] [Related]
20. PPARalpha is a potential therapeutic target of drugs to treat circadian rhythm sleep disorders.
Shirai H; Oishi K; Kudo T; Shibata S; Ishida N
Biochem Biophys Res Commun; 2007 Jun; 357(3):679-82. PubMed ID: 17449013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
